Scientific Advisory Board

Michael Atkins, MD.

Dr. Atkins is Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC and Professor of Oncology and Medicine (Hematology/Oncology) at Georgetown University School of Medicine. He began his career at Tufts Medical Center before moving to Beth Israel Deaconess Medical Center and being appointed Professor at Harvard Medical School where he served as Deputy Chief of the Division of Hematology/Oncology and leader of the Biologic Therapy and Cutaneous Oncology Programs, as well as Co-PI of the Harvard Skin Cancer SPORE, leader of the Dana Farber Harvard Cancer Center Kidney Cancer Program and Director of the DF/HCC Kidney Cancer SPORE. In 2012, he became the Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center and William M. Scholl Professor and Vice Chair of the Department of Oncology. He is the former president of the Society for Immunotherapy of Cancer and currently co-Chair of the Melanoma Research Foundation Scientific Advisory Council. His current research focuses on immunotherapy for melanoma, renal cell carcinoma, and predictive biomarkers for biologic therapy response.

Rakesh Jain, Ph.D.

Dr. Rakesh Jain is widely known for revealing how the abnormal tumor microenvironment fuels tumor progression and confers treatment resistance; developing innovative strategies to “normalize” the microenvironment; and then translating these strategies from bench to bedside. He currently serves as the Andrew Werk Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School, and Director of the Edwin L. Steele Laboratories at Massachusetts General Hospital. A recipient of more than 90 awards, Dr. Jain has the rare distinction of being a member of all three US National Academies –Sciences, Engineering and Medicine – as well as the National Academy of Inventors and the American Academy of Arts and Sciences. He received the 2013 US National Medal of Science (for biological sciences) from President Obama “For pioneering research at the interface of engineering and oncology, including tumor microenvironment, drug delivery, and imaging; and for discovering groundbreaking principles guiding the development and novel use of drugs for cancer and non-cancerous diseases.”

Dennis Benjamin, Ph.D.

Dr. Benjamin is the former SVP of Research at Seattle Genetics where he was a key developer of the company’s ADC technology. Prior to Seattle Genetics he worked at Praecis Pharmaceuticals and Genetics Institute, advancing DNA encoded libraries and working in protein and small molecule discovery. Over his career he has led teams that have discovered 25 biologics and small molecules that entered clinical trials and contributed to 4 drug approvals. He is currently an advisor and SAB member at several start-up biotechnology companies.